Content about Mood disorders

January 22, 2014

Takeda Pharmaceuticals and Lundbeck announced the availability of Brintellix (vortioxetine), a once-daily oral antidepressant for treatment of major depressive disorder in adults.

DEERFIELD, Ill. — Takeda Pharmaceuticals U.S.A. and Lundbeck on Tuesday announced the availability of Brintellix (vortioxetine) — a once-daily oral antidepressant for treatment of major depressive disorder in adults — in pharmacies across the United States.

“MDD continues to be a challenging condition to manage, and we are proud to make Brintellix available as a new treatment option for people struggling with major depression,” said Douglas Cole, president of Takeda Pharmaceuticals U.S.A.

July 1, 2013

The Food and Drug Administration has approved a drug made by Sunovion and Dainippon Sumitomo Pharma Co. for bipolar disorder, Sunovion said.

MARLBOROUGH, Mass. — The Food and Drug Administration has approved a drug made by Sunovion and Dainippon Sumitomo Pharma Co. for bipolar disorder, Sunovion said Monday.

The FDA has approved Latuda (lurasidone hydrochloride) for use either alone or combined with lithium or valproate in patients with bipolar depression. The drug was already approved for treating schizophrenia.

March 7, 2012

A drug under development by Forest Labs and Pierre Fabre "significantly" reduced symptoms of major depressive disorder, the companies said Wednesday.

NEW YORK — A drug under development by Forest Labs and Pierre Fabre "significantly" reduced symptoms of major depressive disorder, the companies said Wednesday.

New York-based Forest and Paris-based Pierre Fabre announced results of a phase-3 trial of levomilnacipran, saying the drug showed reductions in symptoms as early as one week after treatment was started. The companies expect results of another phase-3 trial of the drug this spring.

January 6, 2012

Low levels of vitamin D have been linked to depression, according to UT Southwestern Medical Center psychiatrists working with the Cooper Center Longitudinal Study in a release issued Thursday.

DALLAS — Low levels of vitamin D have been linked to depression, according to UT Southwestern Medical Center psychiatrists working with the Cooper Center Longitudinal Study in a release issued Thursday.

This new study — published in Mayo Clinic Proceedings — helps clarify a debate that erupted after smaller studies produced conflicting results about the relationship between vitamin D and depression. Major depressive disorder affects nearly 1-in-10 adults in the United States.

May 20, 2011

Such mood disorders as anxiety and depression may be a precursor to diabetes in Latinos, according to a study by University of California at San Diego researchers scheduled for presentation at the American Psychiatric Association’s annual meeting in Honolulu.

NEW YORK — Such mood disorders as anxiety and depression may be a precursor to diabetes in Latinos, according to a study by University of California at San Diego researchers scheduled for presentation at the American Psychiatric Association’s annual meeting in Honolulu.

As reported in the Los Angeles Times, the researchers found that while Latinos have higher-than-average rates of diabetes, they also seem to have higher-than-average risk of having both diabetes and a mood disorder.

January 28, 2011

Spouses of older patients with diabetes tend to experience distress if the diabetic patient has symptoms of depression, according to a new study.

WEST LAFAYETTE, Ind. — Spouses of older patients with diabetes tend to experience distress if the diabetic patient has symptoms of depression, according to a new study.

January 24, 2011

The Food and Drug Administration has approved a new drug for treating major depressive disorder, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating major depressive disorder, the agency said Friday.

The FDA announced the approval of Viibryd (vilazodone hydrochloride), made by New Haven, Conn.-based PGxHealth.

August 30, 2010

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital suggested...

BOSTON A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital suggested that the dietary supplement S-adenosylmethionine (SAMe) can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication, Pharmavite announced Tuesday.

August 9, 2010

Drug maker Angelini Labopharm has launched a new treatment for depression....

May 26, 2010

Military service members that experience post-traumatic stress disorder are at risk of developing diabetes, according...